MSD is involved in the development, clinical research, production, and packaging of pharmaceuticals and vaccines, impacting health and welfare for humans and animals.

Biogénesis Bagó focuses on animal health globally. The company provides solutions for both large and companion animals, as self-described.

Biogénesis Bagó

Ceva is a company that develops and produces innovative health solutions for animals, contributing to animal welfare and the future of the planet.

Ceva

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia and New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. It supports customers across various aspects of design, development, and manufacturing. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. In addition, this segment provides specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. The company was founded in 1897 and is headquartered in Basel, Switzerland.

Metric
Company Name	MSD	Biogénesis Bagó	Ceva	Lonza Group AG
Symbol				LONN
MSH ID	NL:MSD	COM:BIOGENESISBAGO	COM:CEVA	COM:LONZA
Market	PRIVATE	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Pharmaceuticals	Veterinary Medicine	Animal Health
Country	NL	AR	FR	CH
Stage
Employee Count				17.90K
Website	msd.nl	biogenesisbago.com	ceva.com	lonza.com
LinkedIn			ceva-sante-animale
Founders

Metric
Market Cap		31.42B
Enterprise Value
Monthly Web Traffic	412.70K
Web Traffic Growth	0.32
Valuation
Raised Capital

Metric
Revenue				7.66B
Revenue (LTM)
Revenue (NTM)
Gross Profit				2.59B
EBITDA				2.26B
Operating Income				1.55B
Net Income				745.51M
EPS				10.12
Diluted EPS				10.12
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin				0.32
Operating Profit Margin				0.21
EBITDA Margin				0.29
Net Profit Margin				0.14
Return on Equity				0.14
Return on Assets				0.08
Return on Capital Employed				0.13

NL:MSD

MSD

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio				27.14
P/B Ratio				3.11
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio				6.29
EV Multiple				20.30

Metric
Days Sales Outstanding
Days Payables Outstanding				46.00
Days Inventory Outstanding				131.99
Operating Cycle				218.98
Cash Conversion Cycle				218.98
Asset Turnover				0.59

Metric
Operating Cash Flow				1.61B
Free Cash Flow				-338.56M
Cash Flow to Debt				0.76
Operating Cash Flow/Sales				0.23
Free Cash Flow Yield				-0.03

Metric
Cash & Equivalents				1.67B
Accounts Receivable
Inventory				1.81B
Goodwill				3.14B
Debt to Capitalization				0.29
Debt to Assets				0.15
Current Ratio				1.86
Quick Ratio				1.38

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue				0.01
R&D to Revenue				0.02
SG&A to Revenue				0.12